Promising Combo for Triple-Negative Breast Cancer, but Only With a BRCA Mutation

The TOPACIO trial tested the PARP inhibitor niraparib plus pembrolizumab in women with triple-negative breast cancer.

Source: CancerNetwork - July 10, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news